Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acamprosate in Schizophrenia with Comorbid Alcoholism
NCT00463346Phase 3Completed
- Sponsor
- Yale University
- Start
- Sep 2006
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in alcohol dependence comparing Acamprosate with Placebo (2 arms). Primary endpoints: Number of Drinking Days at 12 weeks and Positive and Negative Syndrome Scale Score at 12 weeks. Started Sep 2006; status: completed.
02
Drugs
acamprosate
03
Conditions
alcohol dependence
Beyond the preview
Go deeper on NCT00463346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00463346.